Jove
Visualize
Contact Us

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

11.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
11.4K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

6.8K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Cancer discovery·2026
Same author

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.

Blood·2025
Same journal

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same journal

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same journal

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 21, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Primary mediastinal large B-cell lymphoma.

Kerry J Savage1,2

  • 1Centre for Lymphoid Cancer and.

Blood
|September 8, 2021
PubMed
Summary
This summary is machine-generated.

Primary mediastinal large B-cell lymphoma (PMBCL) is distinct from other lymphomas, with unique molecular features. Research is refining diagnosis and treatment, exploring new therapies like PD1 inhibitors for improved outcomes.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

375
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K

Related Experiment Videos

Last Updated: Oct 21, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

375
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.0K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct entity in the WHO classification, sharing features with nodular sclerosis classic Hodgkin lymphoma (cHL).
  • Molecular signatures can differentiate PMBCL from diffuse large B-cell lymphoma (DLBCL), though clinical context is crucial due to overlapping phenotypes.
  • PMBCL biology involves JAK-STAT and NF-κB signaling pathways and immune evasion mechanisms, similar to cHL.

Purpose of the Study:

  • To review the distinct clinicopathologic and molecular features of PMBCL.
  • To discuss the evolving treatment landscape, including the role of rituximab and radiotherapy.
  • To highlight emerging therapeutic strategies, such as PD1 inhibitors, for refractory or upfront treatment.

Main Methods:

  • Review of clinicopathologic features and molecular signatures.
  • Analysis of signaling pathways (JAK-STAT, NF-κB) and immune evasion mechanisms.
  • Evaluation of treatment outcomes in the rituximab era and emerging therapies.

Main Results:

  • Molecular classifiers can distinguish PMBCL from DLBCL, but clinical information is vital for diagnosis.
  • Treatment outcomes for PMBCL have improved with rituximab, yet controversies regarding radiotherapy persist.
  • Refractory disease occurs in up to 10% of patients, correlating with poor prognosis.

Conclusions:

  • PMBCL is a unique lymphoma subtype requiring specific diagnostic and therapeutic approaches.
  • Ongoing research is focused on optimizing frontline therapy and integrating novel agents like PD1 inhibitors.
  • Further studies are needed to establish optimal treatment standards and manage refractory cases.